K. Panageas

2.5k total citations
31 papers, 1.7k citations indexed

About

K. Panageas is a scholar working on Oncology, Genetics and Cancer Research. According to data from OpenAlex, K. Panageas has authored 31 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Genetics and 8 papers in Cancer Research. Recurrent topics in K. Panageas's work include Glioma Diagnosis and Treatment (6 papers), Cancer Treatment and Pharmacology (5 papers) and Breast Cancer Treatment Studies (5 papers). K. Panageas is often cited by papers focused on Glioma Diagnosis and Treatment (6 papers), Cancer Treatment and Pharmacology (5 papers) and Breast Cancer Treatment Studies (5 papers). K. Panageas collaborates with scholars based in United States, Switzerland and United Kingdom. K. Panageas's co-authors include Lisa M. DeAngelis, Alan Z. Segal, Dean M. Cestari, Douglas M. Weine, Anne S. Reiner, Maura N. Dickler, Victor R. Grann, Alfred I. Neugut, Karen H. Antman and William Whang and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and JNCI Journal of the National Cancer Institute.

In The Last Decade

K. Panageas

30 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. Panageas United States 18 607 476 382 359 356 31 1.7k
Fred G. Behm United States 23 399 0.7× 260 0.5× 419 1.1× 270 0.8× 675 1.9× 38 2.3k
Nicole Mentens Belgium 22 449 0.7× 204 0.4× 307 0.8× 360 1.0× 766 2.2× 33 2.4k
Wim van Putten Netherlands 16 603 1.0× 230 0.5× 333 0.9× 727 2.0× 1.4k 3.9× 26 3.4k
Ashish M. Ingle United States 24 788 1.3× 815 1.7× 354 0.9× 383 1.1× 1.2k 3.4× 36 2.5k
Michel Symann Belgium 21 1.3k 2.1× 192 0.4× 508 1.3× 242 0.7× 371 1.0× 95 2.2k
Joke W. Baars Netherlands 23 935 1.5× 349 0.7× 899 2.4× 507 1.4× 348 1.0× 52 2.4k
Gabriella Pichert Switzerland 21 541 0.9× 172 0.4× 507 1.3× 258 0.7× 316 0.9× 46 1.5k
Arend von Stackelberg Germany 32 917 1.5× 199 0.4× 381 1.0× 277 0.8× 583 1.6× 92 3.3k
Kim Linton United Kingdom 24 1.1k 1.8× 408 0.9× 1.2k 3.0× 542 1.5× 421 1.2× 122 2.2k
Amanda F. Cashen United States 29 1.0k 1.7× 443 0.9× 1.4k 3.6× 549 1.5× 629 1.8× 121 2.9k

Countries citing papers authored by K. Panageas

Since Specialization
Citations

This map shows the geographic impact of K. Panageas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Panageas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Panageas more than expected).

Fields of papers citing papers by K. Panageas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Panageas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Panageas. The network helps show where K. Panageas may publish in the future.

Co-authorship network of co-authors of K. Panageas

This figure shows the co-authorship network connecting the top 25 collaborators of K. Panageas. A scholar is included among the top collaborators of K. Panageas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Panageas. K. Panageas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morris, Patrick G., Denise D. Correa, Joachim Yahalom, et al.. (2013). Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome. Journal of Clinical Oncology. 31(31). 3971–3979. 316 indexed citations
2.
Singer, Samuel, Babak B. Navi, Anne S. Reiner, et al.. (2012). Subdural Hematoma in Patients With Cancer. Neurosurgery. 71(1). 74–79. 20 indexed citations
3.
Smyth, Elizabeth, Meier Hsu, K. Panageas, & Paul B. Chapman. (2011). Histology and outcomes of newly detected lung lesions in melanoma patients. Annals of Oncology. 23(3). 577–582. 14 indexed citations
4.
Iwamoto, Fábio M., Andreas F. Hottinger, Sasan Karimi, et al.. (2011). Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro-Oncology. 13(11). 1244–1251. 70 indexed citations
5.
Callahan, Margaret K., Aili Yang, Ya Xu, et al.. (2011). Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis.. Journal of Clinical Oncology. 29(15_suppl). 2505–2505. 102 indexed citations
6.
Khasraw, Mustafa, et al.. (2010). SURVIVAL AND TREATMENT OF CRANIAL METASTASES (CMS) FROM NEUROENDOCRINE TUMORS (NETS) AT MEMORIAL SLOAN-KETTERING CANCER CENTER (MSKCC). Neuro-Oncology. 46–46. 1 indexed citations
7.
Shah, Gaurav, Nicholas D. Socci, Jason S. Gold, et al.. (2010). Phase II trial of neoadjuvant temozolomide in resectable melanoma patients. Annals of Oncology. 21(8). 1718–1722. 30 indexed citations
8.
Rice, Robert D., et al.. (2010). Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients. Bone Marrow Transplantation. 45(10). 1522–1527. 17 indexed citations
9.
Omuro, Antonio, Kathryn Beal, Sasan Karimi, et al.. (2010). Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).. Journal of Clinical Oncology. 28(15_suppl). 2036–2036. 10 indexed citations
10.
Port, Elisa, Kotha Subbaramaiah, Edi Brogi, et al.. (2010). Celecoxib and aromatase activity in breast cancer: Results from a prospective randomized preoperative trial.. Journal of Clinical Oncology. 28(15_suppl). 1527–1527. 1 indexed citations
11.
Scott, James G., A. Cooper, Anne S. Reiner, et al.. (2010). Prognostic factors for glioblastoma (GBM) in individuals age 70 and older: A study of 446 patients from two tertiary centers.. Journal of Clinical Oncology. 28(15_suppl). 2034–2034.
12.
Panageas, K., et al.. (2007). When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival. JNCI Journal of the National Cancer Institute. 99(6). 428–432. 133 indexed citations
13.
Gilewski, Teresa, Govind Ragupathi, Maura N. Dickler, et al.. (2007). Immunization of High-Risk Breast Cancer Patients with Clustered sTn-KLH Conjugate plus the Immunologic Adjuvant QS-21. Clinical Cancer Research. 13(10). 2977–2985. 65 indexed citations
14.
Rugo, Hope S., James F. Caravelli, Benjamin M. Yeh, et al.. (2006). Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC). Journal of Clinical Oncology. 24(18_suppl). 3050–3050. 22 indexed citations
15.
Raizer, Jeffrey J., Jason A. Koutcher, Lauren E. Abrey, et al.. (2005). Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma. Journal of Neuro-Oncology. 71(2). 173–180. 36 indexed citations
16.
Heffner, Leonard T., Nicole Lamanna, M Kalaycio, et al.. (2005). A randomized trial of cytarabine with high-dose mitoxantrone compared to a standard vincristine/prednisone-based regimen as induction therapy for adult patients with ALL. Journal of Clinical Oncology. 23(16_suppl). 6516–6516. 7 indexed citations
17.
Gyorki, David, Klaus J. Busam, K. Panageas, Mary Sue Brady, & Daniel G. Coit. (2003). Sentinel Lymph Node Biopsy for Patients With Cutaneous Desmoplastic Melanoma. Annals of Surgical Oncology. 10(4). 403–407. 75 indexed citations
18.
Seidman, Andrew D., Maria Theodoulou, Mary Ellen Moynahan, et al.. (2001). Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.. PubMed. 7(12). 3934–41. 25 indexed citations
19.
Hudis, Clifford A., Monica Fornier, David Lebwohl, et al.. (1999). 5-Year Results of Dose-Intensive Sequential Adjuvant Chemotherapy for Women With High-Risk Node-Positive Breast Cancer: A Phase II Study. Journal of Clinical Oncology. 17(4). 1118–1118. 43 indexed citations
20.
Grann, Victor R., K. Panageas, William Whang, Karen H. Antman, & Alfred I. Neugut. (1998). Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.. Journal of Clinical Oncology. 16(3). 979–985. 161 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fred G. Behm Breakdown of academic impact, for papers by Nicole Mentens Breakdown of academic impact, for papers by Wim van Putten Breakdown of academic impact, for papers by Ashish M. Ingle Breakdown of academic impact, for papers by Michel Symann Breakdown of academic impact, for papers by Joke W. Baars Breakdown of academic impact, for papers by Gabriella Pichert Breakdown of academic impact, for papers by Arend von Stackelberg Breakdown of academic impact, for papers by Kim Linton Breakdown of academic impact, for papers by Amanda F. Cashen
Rankless by CCL
2026